Jump to content

DOPF

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Graeme Bartlett (talk | contribs) at 00:31, 8 September 2021 (added Category:Organofluorides using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

DOPF
Identifiers
  • 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H22FNO2
Molar mass255.333 g·mol−1
3D model (JSmol)
  • COc1cc(CCCF)c(cc1CC(C)N)OC
  • InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3
  • Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N

DOPF is a designer drug from the substituted amphetamine family. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans.[1]

See also

References

  1. ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.